GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Equity-to-Asset

Revelation Biosciences (FRA:56U0) Equity-to-Asset : 0.54 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Revelation Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €6.10 Mil. Revelation Biosciences's Total Assets for the quarter that ended in Dec. 2023 was €11.20 Mil.

The historical rank and industry rank for Revelation Biosciences's Equity-to-Asset or its related term are showing as below:

FRA:56U0' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.05   Med: 0.37   Max: 0.74
Current: 0.54

During the past 4 years, the highest Equity to Asset Ratio of Revelation Biosciences was 0.74. The lowest was -0.05. And the median was 0.37.

FRA:56U0's Equity-to-Asset is ranked worse than
60.64% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:56U0: 0.54

Revelation Biosciences Equity-to-Asset Historical Data

The historical data trend for Revelation Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Equity-to-Asset Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.74 -0.05 0.19 0.54

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.55 0.71 0.62 0.54

Competitive Comparison of Revelation Biosciences's Equity-to-Asset

For the Biotechnology subindustry, Revelation Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Equity-to-Asset falls into.



Revelation Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Revelation Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6.096/11.199
=

Revelation Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6.096/11.199
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences  (FRA:56U0) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Revelation Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences (FRA:56U0) Business Description

Traded in Other Exchanges
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines